Five-year potency preservation after iodine-125 prostate brachytherapy
International Journal of Clinical Oncology,  Clinical Article

Nishimura S, et al. – The authors aimed to evaluate long–term erectile function following prostate brachytherapy, based on patient characteristics and treatment factors. Patient age at implantation and pre–treatment erectile function are predictive factors for the development of erectile dysfunction following prostate brachytherapy.

Methods

  • Between 2003 and 2006, 665 men with localized prostate cancer were treated with 125I permanent seed implantation.
  • None was given adjuvant hormone therapy.
  • Erectile function was assessed before treatment, and at 6 months, 1, 2, 3, 4 and 5 years after implantation using the Mount Sinai Erectile Function Score (MSEFS) of 0–3 (0 = no erections, 1 = erections insufficient for intercourse, 2 = suboptimal erections but sufficient for intercourse, 3 = normal erectile function).
  • Potency was defined as score 2 or 3, and 382 men were potent before treatment.
  • Univariate and multivariate analyses were performed on the data from these 382 patients to identify variables associated with potency preservation.

Results

  • In patients who were potent before treatment, the actuarial potency preservation rate fell to 46.2 % at 6 months after brachytherapy, and then slowly recovered reaching 52.0 % at 5 years after brachytherapy.
  • In multivariate logistic regression analysis, patient age (p = 0.04) and pre–treatment MSEFS (p < 0.001) were predictors of 5–year potency preservation.
  • Neoadjuvant hormone therapy affected potency preservation only at 6 months after brachytherapy.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Urology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Urology Articles

1 Who dies from prostate cancer? Prostate Cancer & Prostatic Diseases, October 17, 2014    Clinical Article

2 The use of metformin in patients with prostate cancer and the risk of death Cancer Epidemiology, Biomarkers & Prevention, September 22, 2014    Clinical Article

3 Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer Urologia Internationalis, October 21, 2014    Clinical Article

4 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

5 The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml Cancer Epidemiology, September 26, 2014    Clinical Article

6 Prevention and early detection of prostate cancer The Lancet Oncology, October 7, 2014    Review Article

7 Highly-trained dogs' olfactory system detects prostate cancer in urine samples The Journal of Urology, October 20, 2014    Clinical Article

8 Concordance between biopsy and radical prostatectomy specimen gleason score in internal and external pathology facilities Anticancer Research, October 22, 2014    Clinical Article

9 Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on-line data registry The Prostate, October 9, 2014    Clinical Article

10 Particle radiotherapy for prostate cancer International Journal of Urology, October 23, 2014    Review Article

11 Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark International Journal of Cancer, October 2, 2014    Clinical Article

12 Biologic differences between peripheral and transition zone prostate cancer The Prostate, October 28, 2014    Clinical Article

13 Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation The Journal of Urology, October 30, 2014    Clinical Article

14 Smoking and risk of low- and high-grade prostate cancer: Results from the REDUCE study Clinical Cancer Research, September 19, 2014    Clinical Article

15 Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) The Prostate, October 1, 2014    Clinical Article

16 Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy The Prostate, October 29, 2014    Clinical Article

17 Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: A systematic review with meta-analyses Clinical Oncology, August 8, 2014    Evidence Based Medicine    Review Article

18 Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer Urologic Oncology: Seminars and Original Investigations, October 16, 2014    Clinical Article

19 Stereotactic body radiation therapy for prostate cancer: Review of experience of a multicenter phase I/II dose escalation study Frontiers in Oncology, October 13, 2014    Review Article    Clinical Article

20 Silodosin for the treatment of clinical benign prostatic hyperplasia: Safety, efficacy, and patient acceptability Full Text Research and Reports in Urology, October 6, 2014    Free full text    Review Article

Indexed Journals in Urology: Urology, Journal of Urology, European Urology, The Prostatemore